FTC angry as Supreme Court lets AbbVie off the hook over AndroGel case
The Federal Trade Commission (FTC) has expressed its disappointment at a Supreme Court decision relating to AndroGel (testosterone gel), a prescription medicine used to treat the symptoms of testosterone deficiency.
This case dates back to 2014, when the FTC filed a complaint in federal district court, charging that US drugmaker AbbVie (NYSE: ABBV) and its partner, privately-held Besins Healthcare, illegally blocked patients’ access to lower-cost alternatives to AndroGel, allegedly by filing baseless patent infringement lawsuits against potential generic competitors.
"Congress should act quickly to restore Section 13(b) of the FTC act and the commission’s ability to return to consumers money lost due to illegal anticompetitive behavior by pharmaceutical companies"It was also alleged that AbbVie settled one of its infringement lawsuits with an illegal reverse-payment agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze